Navigation Links
OBN's 2013 Annual Awards Dinner Celebrates UK Bioscience Success Stories
Date:10/1/2013

OXFORD, England, October 1, 2013 /PRNewswire/ --


 http://www.obn.org.uk/obn_/menu.php?p=rss&rn=rssfeed&prechk_news=1

OBN's Annual Awards Dinner this evening celebrated the achievements and major success stories in biotech, medtech and diagnostics over the past year at a black tie event at The Ashmolean Museum, Oxford. The Awards seek to highlight the many achievements of the UK's bioscience sector in raising funds, executing deals and supporting innovation. OBN's Awards recognize these achievements, taking into account its significance for the stage of development of a nominated life sciences company, as well as the scale of the achievement.

The 2013 award winners were:

Circassia, Best New Biotech Development Programme

Award Presented by J A Kemp

Circassia's ToleroMune® cat allergy treatment maintained symptom improvement two years after the start of Short-Course Therapy in a phase II clinical trial, while their HDM-SPIRE treatment for house dust mite allergy also achieved long-term symptom reduction.

OrganOx, Best New Medtech Development Programme

Award Presented by Citigate

OrganOx has developed metra™ - a system which enables the repair, preservation and objective viability assessment of livers prior to transplantation. It has already been used successfully for several transplantation procedures in 2013.

Autifony Therapeutics, Best Emerging Biotech

Award Presented by James Cowper

Autifony is developing new drugs to treat hearing disorders by targeting specific ion channels which regulate neuronal activity within the auditory system. A top up series A round of £5.5m in June 2013 brings funds raised to £15.5m, plus a £2.75m collaboration also announced in 2013.

Parsortix, Best Emerging Medtech

Award Presented by Team Consulting

Angle plc spin-out Parsortix has separation technology which captures very rare circulating tumour cells (CTCs) in cancer patient blood. They have launched a research market product but also aim to secure CE Mark approval for the clinical market in 2013, with FDA approval sought during 2014.

Karus Therapeutics, Best Biotech Fundraiser

Award Presented by Akesios Associates

Karus raised £5m as the first tranche of a Series B investment in September 2012 from top tier investors SV Life Sciences (UK and International), New Leaf Venture Partners (US), Novo A/S (Denmark), IP Group (UK), Esperante Ventures (Netherlands) and a number of Angel investors. This award recognizes the progression the company has made in securing this fundraising from this syndicate.

Glide Pharma, Best Medtech Fundraiser

Award Presented by Milton Park

Glide Pharma raised £14m in Feb 2013 from Invesco Perpetual and existing investors.  This will enable the scale-up of manufacturing for its Glide SDI injector system (both drug and device).  Glide won an additional £2.3m of project funding from TSB in the form of a Biomedical Catalyst competition award.

Immunocore,  Best Biotech Dealmaker

Award Presented by E&Y

Immunocore secured a £142m deal with GSK (July 2013) for ImmTACs to treat cancer and viral disease and a research collaboration and licensing agreement with Genentech (June 2013), valued at up to £300m. The deals come with potential fees and milestone payments which could be worth hundreds of millions according to industry commentators.

Oxford Gene Technology,  Best Medtech Dealmaker

Award Presented by Wilmerhale

Oxford Gene Technology collaboratively developed  a panel of 58 cancer-associated genes for diagnostic purposes with Birmingham and Salisbury NHS Regional Genetics Laboratories backed by £1.16m in funding from the TSB (May 2013).

Technology Strategy Board,  Highest Impact Investor

Award Presented by OBN

This award is made to the TSB in recognition of the impact of the Biomedical Catalyst, making investments of up to £122m over its first 18 months, including up to 112 awards to small-to-medium sized companies in the sector.

Shire,  Best Pharma BD&L Team

Award Presented by World Courier

Shire strengthened its rare disease and opthalmology portfolio with a number of significant acquisitions including Premacure AB, Lotus Tissue Repair, and SARCode Bioscience, and entered into a number of new co-development deals.

Dr Jon Rees, OBN's CEO, said: "This year's awards highlight the vibrancy and variety of the broader life sciences sector in the UK and, despite tough financing conditions, the progress companies have been able to make and the tangible successes delivered. As OBN expands its sphere of influence across the UK, we were delighted to welcome a larger number of entrepreneurs from across the UK to the Awards Dinner than any previous year."

**Photographs of the Awards are available on request**


About OBN


OBN is the membership organisation supporting and bringing together the UK's emerging life science companies, corporate partners and investors within the Golden Triangle biocluster (formed by the cities of Oxford, Cambridge and London) and beyond, providing networking, partnering, group purchasing, advocacy and cluster consultancy.

Through our delivery of Europe's third largest annual biopartnering and investment conference 'BioTrinity', which is expected to attract 1000+ delegates from 30 countries, OBN will generate more R&D-company-to-investor interactions than anyone else in Europe.

For further information on OBN and its activities, please visit: http://www.obn.org.uk or to find out more about BioTrinity, please visit http://www.biotrinity.com

Contacts

OBN
David Boal, Director of Business Development
Tel: +44(0)845-5049-743
david.boal@obn.org.uk


Citigate Dewe Rogerson
Janine Hagan
Tel: +44(0)20-7638-9571
Janine.Hagan@citigatedr.co.uk


'/>"/>
SOURCE OBN
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. iLab Solutions to Present at the Midwest Association of Core Directors Annual Meeting
2. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
3. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
4. RXi Pharmaceuticals to Present at the 12th Annual BIO Investor Forum
5. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
6. Verenium To Present At The Rodman & Renshaw Annual Global Investment Conference
7. Neuralstem President And CEO To Present At The 2013 Rodman & Renshaw Annual Healthcare Conference
8. Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
9. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
10. 6th BSMA Annual Executive Summit to Address the Supply Chain Challenges and Solutions of Biopharma
11. Fourth Annual U.S. Symposium at JASIS Organized by Pittcon’s Amit Ghosh and Koichiro Matsuda (Horiba)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments ... host live demos and poster sessions, and present on the analysis of mycotoxins ... place March 6 to 10 at the Georgia World Congress Center in Atlanta, ...
(Date:2/4/2016)... and MENLO PARK, Calif. , ... DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on ... that it will present at the 18 th ... 8, 2016 at 10:00 a.m. EST in New ... DelMar,s president and CEO, will provide an update on the ...
(Date:2/4/2016)... 2016 Sinovac Biotech Ltd. ("Sinovac" or the ... biopharmaceutical products in China , today ... directors received on February 4, 2016 a preliminary non-binding ... comprised of PKU V-Ming ( Shanghai ) ... Qianhai Development ( Shenzhen ) Fund Management ...
(Date:2/3/2016)...   ViaCyte, Inc ., a leading, privately-held ... cell-derived islet replacement therapy for the treatment of ... that ViaCyte and Janssen Biotech, Inc., one of ... have agreed to consolidate the assets of the ... ViaCyte with an exclusive license to all BetaLogics ...
Breaking Biology Technology:
(Date:1/8/2016)... LOS ANGELES and MANCHESTER, United Kingdom ... ("BBI"), a developer of innovative sensor-based diagnostic products, today ... was financed by new and existing investors.  Proceeds from the ... SEM Scanner , a hand-held device for detecting early-stage ... and Ireland after receiving CE Mark ...
(Date:1/7/2016)... 7, 2016 Various factors have contributed ... such as biologics and biosimilars. Some of these ... expenditure, growing demand for cost-effective alternatives, growing burden ... are similar versions of their corresponding patented biologic ... quality, safety, and efficacy. The global biosimilars market ...
(Date:1/6/2016)... 2016 Based on its recent analysis ... recognizes MorphoTrak, LLC, a U.S. subsidiary of Morpho ... Sullivan Company of the Year Award. The success ... Wave™ , has consolidated the company,s position as ... Morpho Wave is a highly accurate and ...
Breaking Biology News(10 mins):